Acute On Chronic Liver Failure (ACLF) Market Report 2026

Acute On Chronic Liver Failure (ACLF) Market Overview

• Acute On Chronic Liver Failure (ACLF) market size has reached to $2.88 billion in 2025 • Expected to grow to $4.13 billion in 2030 at a compound annual growth rate (CAGR) of 7.4% • Growth Driver: Rising Impact Of Precision And Personalized Medicine On Healthcare Advancements • Market Trend: Advancements In Clinical Trials For Improved Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Acute On Chronic Liver Failure (ACLF) Market?

Acute on chronic liver failure (ACLF) is a severe condition characterized by acute hepatic decompensation in patients with pre-existing chronic liver disease. This deterioration triggers systemic inflammation, contributing to the progressive failure of multiple organs. The condition is associated with a high risk of mortality, requiring prompt diagnosis and intensive medical management. The main types of treatment in the acute on chronic liver failure (ACLF) market are pharmacological and supportive care. Pharmacological treatment for acute-on-chronic liver failure (ACLF) refers to the use of medications such as antibiotics, vasopressors, corticosteroids, albumin therapy, and liver-specific drugs to manage infections, reduce inflammation, support organ function, and stabilize the patient before potential liver transplantation. The various modes of administration include oral and intravenous (IV), and several end-users including hospitals, ambulatory surgical centers, and specialty clinics.

What Is The Acute On Chronic Liver Failure (ACLF) Market Growth Forecast?

The acute on chronic liver failure (aclf) market size is expected to see strong growth in the next few years. It will grow to $4.13 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to technological advancements in liver support therapies, expansion of icu and specialty care facilities, increasing investment in pharmacological research, growth in early diagnosis and biomarker identification, integration of digital monitoring and patient management systems. Major trends in the forecast period include increasing adoption of liver dialysis and plasma exchange, rising demand for advanced immunomodulators and antiviral agents, growing focus on nutritional support and patient management, expansion of mechanical ventilation and renal replacement therapy (rrt), improved early diagnosis and monitoring of aclf patients.

Global Acute On Chronic Liver Failure (ACLF) Market Segmentation

1) By Type Of Treatment: Pharmacological, Supportive Care 2) By Mode Of Administration: Oral, Intravenous (IV) 3) By End-User: Hospitals, Tertiary Care Centers or Liver Transplant Centers, Intensive Care Units (ICUs), Specialty Hepatology Clinics Subsegments: 1) By Pharmacological: Antibiotics, Vasopressors 2) By Supportive Care: Liver Dialysis, Plasma Exchange, Nutritional Support, Mechanical Ventilation, Renal Replacement Therapy (RRT)

What Is The Driver Of The Acute On Chronic Liver Failure (ACLF) Market?

The increasing focus on precision and personalized medicine is expected to propel the growth of the acute-on-chronic liver failure market going forward. Precision and personalized medicine involve tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The use of precision and personalized medicine is increasing due to factors such as advancements in genomics, growing availability of biomarker-based diagnostics, improved data analytics technologies, and a rising demand for more targeted and effective therapies. Precision and personalized medicine support acute-on-chronic liver failure (ACLF) by customizing treatments according to a patient’s genetic makeup, disease severity, and biomarker insights, allowing for targeted therapies that enhance outcomes and lower the risk of multi-organ failure. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the increasing focus on precision and personalized medicine is driving the growth of the acute-on-chronic liver failure market.

Key Players In The Global Acute On Chronic Liver Failure (ACLF) Market

Major companies operating in the acute on chronic liver failure (aclf) market are Pfizer Inc., F Hoffmann La Roche AG, Merck and Co Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca plc, GSK plc, Eli Lilly and Company, Gilead Sciences Inc, Novo Nordisk AS, Astellas Pharma Inc., CSL Behring, Grifols SA, Ferring Pharmaceuticals, Lupin Pharmaceutical Limited, Dr Falk Pharma GmbH, Genfit, Conatus Pharmaceuticals Inc., Gyre Therapeutics Inc., Abbott Laboratories

Global Acute On Chronic Liver Failure (ACLF) Market Trends and Insights

Major companies operating in the acute-on-chronic liver failure (ACLF) market are focusing on conducting clinical trials to develop novel therapeutics, regenerative medicine approaches, and targeted drug therapies aimed at improving patient survival rates. Clinical trials are crucial for validating new treatment protocols, artificial liver support systems, and immunomodulatory therapies to enhance disease management and reduce mortality. For instance, in September 2024, A-TANGO, a Spain-based EU Horizon-funded project, would conduct the clinical "G-TAK trial" in several liver centers in the UK, aiming to help critically ill patients who suffer from alcoholic hepatitis and acute-on-chronic liver failure (ACLF). G-TAK is a combinatorial therapy with a toll-like 4 receptor antagonist (TAK242) that targets inflammation in combination with granulocyte colony-stimulating factor (G-CSF, TRL9) that improves hepatocyte proliferation, thereby treating acute-on-chronic liver failure (ACLF).

What Are Latest Mergers And Acquisitions In The Acute On Chronic Liver Failure (ACLF) Market?

In June 2024, the European Foundation for the Study of Chronic Liver Failure (EF CLIF), a Spain-based research foundation, entered into a partnership agreement with GENFIT to advance research and therapies for acute on chronic liver failure (ACLF). Through this collaboration, EF CLIF and GENFIT aim to deepen research into acute on chronic liver failure (ACLF), exploring novel therapeutic strategies to better understand its pathophysiology, develop predictive biomarkers, and identify treatment targets. GENFIT is a France-based late-stage biopharmaceutical company focused on liver disease, bringing a pipeline of five ACLF-targeted assets.

Regional Outlook

North America was the largest region in the acute on chronic liver failure (ACLF) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Acute On Chronic Liver Failure (ACLF) Market?

The acute on chronic liver failure (ACLF) market consists of revenues earned by entities by providing services such as diagnostic evaluations, intensive care management, liver function monitoring, hemodialysis, extracorporeal liver support therapies, nutritional support, palliative care and liver transplantation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute on chronic liver failure (ACLF) market also includes sales of diagnostic tools and liver support devices aimed at managing disease progression and improving patient outcomes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Acute On Chronic Liver Failure (ACLF) Market Report 2026?

The acute on chronic liver failure (aclf) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the acute on chronic liver failure (aclf) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.